Pharmaceutically active isoindoline derivatives

Details Pharmaceutically active isoindoline derivatives Pharmaceutically active isoindoline derivatives

2003-10-14

2011-10-04

Landau, Sharmila G. (Department: 1611)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S364000, C514S383000, C514S397000, C514S412000, C514S414000, C514S417000

Reexamination Certificate

active

08030343

ABSTRACT:
Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with an α-(3,4-disubstituted phenyl)alkyl group and in the 4- and/or 5-position with a nitrogen-containing group are inhibitors of, and thus useful in the treatment of disease states mediated by, TNFα and phosphodiesterase. A typical embodiment is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4,5-diaminoisoindoline-1,3-dione.

REFERENCES:
patent: 4173652 (1979-11-01), Bruins et al.
patent: 4556673 (1985-12-01), Anderson et al.
patent: 4820828 (1989-04-01), Demers et al.
patent: 5463063 (1995-10-01), Muller
patent: 5605914 (1997-02-01), Muller
patent: 5658940 (1997-08-01), Muller et al.
patent: 5698579 (1997-12-01), Muller
patent: 5703098 (1997-12-01), Muller et al.
patent: 5728844 (1998-03-01), Muller et al.
patent: 5728845 (1998-03-01), Muller et al.
patent: 5736570 (1998-04-01), Muller et al.
patent: 5801195 (1998-09-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller et al.
patent: 5929117 (1999-07-01), Muller et al.
patent: 5968945 (1999-10-01), Muller et al.
patent: 6011050 (2000-01-01), Muller et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6046221 (2000-04-01), Muller et al.
patent: 6075041 (2000-06-01), Muller
patent: 6214857 (2001-04-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6429221 (2002-08-01), Muller et al.
patent: 6458810 (2002-10-01), Muller et al.
patent: 6667316 (2003-12-01), Man et al.
patent: 6699899 (2004-03-01), Man et al.
patent: 6762195 (2004-07-01), Muller et al.
patent: 6911464 (2005-06-01), Man et al.
patent: 6962940 (2005-11-01), Muller et al.
patent: 7005438 (2006-02-01), Muller et al.
patent: WO 97/05105 (1997-02-01), None
patent: WO 97/23457 (1997-03-01), None
patent: WO 97/24117 (1997-07-01), None
patent: WO 98/24763 (1998-06-01), None
Harrison's Principles of Internal Medicine (1994), pp. 1543-1566.
Lavoie et al. Lack of clinical efficacy of a phosphodiesterase-4 inhibitor for treatment of heaves in horses. Journal of veterinary internal medicine. 2006;20(1): 175-181, abstract only.
Clinical Trails.gov. Safety study of clinical and immune effects of PDE-4 inhibitor in cutaneous lupus patients. Jun. 22, 2008, pp. 1-4.
Anonymous. Ariflo (Cilomilast)—Oral PDE-IV Inhibitor for Chronic Obstructive Pulmonary Disease (COPD). www.drugdevelopment-technology.com/projects/ariflo. Electronic pp. 1-2.
Bielekova et al., The Journal of Immunology,164(2), pp. 1117-1124 (2000).
Burnouf et al., Current Pharmaceutical Design, 8, pp. 1255-1296 (2002).
Haack et al., Bioorganic & Medicinal Chemistry, 13, pp. 4425-4433 (2005).
Shire et al., Exp. Opin. Ther. Patents, 8: 531-544 (1998).
He et al., J. Med. Chem., 41: 4216-4223 (1998).
Draetta et al., in “Annual Reports in Medicinal Chemistry vol. 31,” Academic Press, San Diego, 241-246 (1996).
Salmon et al., in “Cecil Textbook of Medicine, 20thEd.,” W.B. Saunders, Philadelphia, 1036-1049 (1996).
Balasubramanian et al., in “Annual Reports in Medicinal Chemistry vol. 33,” Academic Press, San Diego, 151-159 (1998).
Miller, in “Cecil Textbook of Medicine, 20thEd.,” W.B. Saunders, Philadelphia, 1071-1077 (1996).
De et al., J. Pharm. Sci., 64(2): 262-266 (1975).
Barnes, Eur. Respir. J., 8: 457-462 (1995).
Bazzoni et al., “Seminars in Medicine of the Beth Israel Hospital, Flier Ed.,” Boston, 331(26): 1717-1725 (1996).
Burnouf et al., in “Annual Reports in Medicinal Chemistry vol. 33,” Academic Press, San Diego, 91-109 (1998).
Buu-Ho et al., JMC, 13(2): 211-213 (1970).
Badger et al., DDT, 2(10): 427-435 (1997).
Beutler et al., Critical Care Medicine, 21(10): S423-S435 (1993).
Corral et al., Molecular Medicine, 2(4): 1076-1551 (1996).
deBrito et al., Emerging Drugs, 2: 249-268 (1997).
Denis et al., Investigational New Drugs, 15: 175-185 (1997).
Eger et al., Arzneim-Forsch/Drug Res., 40(II): 1073-1075.0 (1990).
Friderichs, Arzneim-Forsch/Drug Res., 32(1), 6: 613-620 (1982).
Hart et al., J. Org. Chem., 48: 289-294 (1983).
Hughes et al., DDT, 2(3): 89-101 (1997).
Kleinman et al., J. Med. Chem., 41: 266-270 (1998).
Lombardo, Current Pharmaceutical Design, 1(2): 255-268 (1995).
Lee et al., Circulatory Shock, 44: 97-103 (1995).
Levy et al., J. Med. Chem., 41: 199-223 (1998).
Müller et al., TIPS, 17: 294-298 (1997).
Marriott, Exp. Opin. Ivest. Drugs, 6(8): 1105-1108 (1997).
Muller et al., Bioorganic & Medicinal Chemistry Letters, 8: 2669-2674 (1998).
Muller et al., J. Med. Chem., 39(17): 3238-3240 (1996).
Natchus et al., Bioorganic & Medicinal Chemistry Letters, 8: 2077-2080 (1998).
Naafs et al., International Journal of Dermatology, 24(2): 131-134 (1985).
Palfreyman, Drugs of the Future, 30(8): 793-804 (1995).
Palacios et al., Il Farmaco, 50(12): 819-827 (1995).
Summers et al., Annual Reports in Medicinal Chemistry, 33: 131-140 (1998).
Steinman et al., Bioorganic & Medicinal Chemistry Letters, 8: 2087-2092 (1998).
Strieter et al., Critical Care Medicine, 21(10): S447-S463 (1993).
Torphy et al., DN&P, 6(4): 203-214 (1993).
Torphy et al., Am J. Resp. Crit. Care Med., 157: 351-370 (1998).
Torphy, Asthma, 1755-1773 (1997).
Teixeira et al., TIPS, 18: 164-170 (1997).
Tracey et al., Annu. Rev. Cell Biol., 9: 317-343 (1993).
Tanaka et al., Chem. Pharm. Bull., 31(8): 2810-2819 (1983).
Wojtowicz-Praga et al., Investigational New Drugs, 16: 61-75 (1997).
Yu et al., Drugs & Aging, 11(3): 229-244 (1997).
Crocker et al., Drug of Today, 35(7): 519-535 (1999).
Norman, Exp. Opin. Ther. Patents, 9(8): 1101-1118 (1999).

Affiliated with

Also associated with

Rating

Pharmaceutically active isoindoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutically active isoindoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active isoindoline derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4260354